Associate Professor Kathryn Skelding
Associate Professor
School of Biomedical Sciences and Pharmacy (Medical Biochemistry)
- Email:kathryn.skelding@newcastle.edu.au
- Phone:(02) 4921 5982
Cells, signalling and cancer therapies
From an early age, Dr Kathryn Skelding was fascinated by how the body works, and this focus continues to drive her desire to understand how diseases develop and how they can be treated.
A molecular biologist with expertise in cell biology, Kathryn believes that if we can understand the processes of cancer cell proliferation, survival and the development of resistance to chemotherapeutics, we can develop new, targeted anti-cancer therapies.
An early career researcher with an expertise spanning from fundamental biochemistry to clinical evaluation of new anti-cancer therapeutics, Kathryn has already made important contributions to science. And it’s her innate curiosity that’s driven her work.
"I always wanted to know why – why does that disease develop? How does that treatment work?" Kathryn says.
"So it was just natural that I would become a medical researcher who investigates the causes of diseases, so that we can develop new and better treatments." This curiosity continued throughout her undergraduate studies, where Kathryn graduated with first class Honours and the University Medal in Biomedical Science from UON.
The development of new targeted therapies for a varieties of cancer was an early theme of her research; Kathryn’s doctoral studies examined the use of novel oncolytic viruses as treatments for breast cancer, and were funded by a National Breast Cancer Foundation Scholarship. Phase I trials for these viruses showed that they were safe and well-tolerated, with evidence of disease stabilisation.
Kathryn’s choice of research field was greatly influenced by personal experience, as several people close to her have been affected by cancer. "While it's well-known that side effects are associated with chemotherapy, it's only when you actually see what these drugs do to someone that it really hits home how toxic they are," she says.
Her research is focussed on brain cancer, leukaemia, breast cancer and prostate cancer – but it is the first two topics that hold Kathryn’s strongest focus. “Both leukaemia and brain cancer are unique in that they have very poor outcomes that have remained unchanged for decades. Both diseases are still fairly under-researched and the survival rates have remained static – we need more research into these areas.”
Kathryn studies how cancer cells function so that she can better understand how cancer cells grow, spread and develop resistance to chemotherapy drugs. "If scientists can better understand these processes, we can develop new treatments for cancer that are more cancer-cell specific and have fewer side effects," she says.
Kathryn is exploring the role of targeting in regulating cancer cell proliferation, invasion and resistance to chemotherapy, exploring how novel inhibitors can play a role in targeting pathways. The aim is to develop new therapies and kill the cancer cells – with maximum effectiveness, while minimising side-effects.
Cell biology and leukaemia
With her leukaemia research, Kathryn’s team is focussed on a protein molecule called BAALC (brain and acute leukaemia, cytoplasmic), which is associated with aggressive disease that is more likely to recur, and also indicate that chemotherapeutic drugs may not be effective against these leukaemia cells. "My lab focuses on a molecule that is present in high amounts in leukaemia cells, and that we have shown is involved in controlling cancer cell growth and survival."
Kathryn has dedicated her attention to developing a new inhibitor for this molecule, and the results are promising. This inhibitor is currently being developed with Newcastle Innovation, a University of Newcastle company that bridges gaps between technology and commercial partners, with the aim of introducing these technologies into clinical use.
Working closely with her colleagues in the University's Priority Research Centre for Cancer, and through her association with the Hunter Medical Research Institute (HMRI) Kathryn has also established important links and relationships with clinical oncologists which continues to fuel her research.
Over her career, Kathryn has been successfully awarded funding from a broad range of bodies, which is vital to translating research findings into the clinic. With so many exciting outcomes in her early research career, Kathryn’s focussed research is bound to lead to treatments which can not only lead to improved patient outcomes – but a better quality of life.
Cells, signalling and cancer therapies
Dr Kathryn Skelding focusses on cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics.
Career Summary
Biography
Dr Skelding is an early mid career researcher, who was appointed to a full-time continuing lecturing position at the start of 2012. Her research focuses on understanding cancer cell biology, specifically how cancer cells proliferate, metastasise, and develop resistance to chemotherapeutics. If these processes can be better understood, new targeted anti-cancer therapies can be discovered. Dr Skelding's PhD investigated the use of oncolytic viruses as novel anti-cancer agents, and was funded by a National Breast Cancer Foundation (NBCF) Scholarship, as well as the commercial company, Viralytics Ltd.
During her PhD, Dr Skelding developed new clinically relevant mouse models of spontaneously metastasising breast cancer, which allowed her to examine the pre-clinical effectiveness of novel viral therapies for cancer, both as single agents, and in combination with currently approved chemotherapeutic agents.
Additionally, the research undertaken throughout Dr Skelding's PhD has led to the commencement of clinical trials in the use of this virus (CAVATAK) as an intravenous treatment for melanoma, breast, and prostate cancer. In her post-doctoral studies, Dr Skelding further applied her background in cell biology to examine signal transduction pathways and the role of targeting in regulating CaMKII (calcium/calmodulin-stimulated protein kinase II) function in neuronal cells.
Since completing her post-doctoral studies in 2012, she has established her own research group that focuses on better understanding cell signalling in cancer, with a view to developing new therapies that are cancer cell-specific and suitable for the treatment of a range of cancers, with a focus on leukaemias (specifically acute myeloid leukaemia, and childhood acute lymphoblastic leukaemia), glioblastoma multiforme, breast cancer and prostate cancer.
Dr Skelding has received several awards throughout her research career, including the Newcastle Innovation Excellence in Innovation Award (2015), the Hunter Cancer Research Alliance Excellence in Translational Research Award (2014), International Society for Neurochemistry Travel Award (2011), Best Early Career Researcher Speaker at the Hunter Medical Research Institute Cancer Research Program Symposium (2010), Best Speaker at the University of Newcastle Graduate Student’s Day (2006), University Medal in Biomedical Science (2003), the University of Newcastle Vice Chancellor’s Award for Academic Excellence (2000), and numerous undergraduate and post-graduate training scholarships. Due to work completed throughout her PhD, the Hon Roslyn Kelly (Chair of the National Breast Cancer Foundation Board of Trustees) nominated Dr Skelding for a Fresh Science Award in 2006, for which she was short-listed.
Dr Skelding's overarching research aim is improve patient outcomes and quality of life, by translating her research findings into the clinic.
Research ExpertiseDr Skelding's research interests focus on examining signal transduction pathways and the role of targeting in regulating cancer cell proliferation, invasion/migration and chemotherapy resistance, so that new targets for controlling these cellular functions can be identified. Using a variety of molecular, biochemical and cellular techniques (including siRNA and overexpression transfection of cancer and normal cell lines, western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, proliferation assays, cell survival assays, flow cytometry, invasion and migration assays), she has identified new pathways involved in these processes. Additionally, she has developed novel inhibitors that can target these pathways. Dr Skelding is currently examining the efficacy of these new drugs in a range of cancer types, including acute myeloid and lymphoblastic leukaemia, breast cancer and prostate cancer.
Teaching Expertise
Cell biology Biochemistry Molecular biology
Administrative Expertise
Dr Skelding is the Deputy Chair of the University of Newcastle Faculty of Health Occupational Health and Safety Committee, a member of the Scientific Committee for the Hunter Cancer Biobank, and has been on the organising committee for several conferences and symposium days. Dr Skelding is also on the editorial board of two International Journals: BMC Cancer and Frontiers in Oncology (Cancer Molecular Targets).
Collaborations
Dr Skelding's interest in the regulation of protein function via targeting has led to her forming local, national, and international collaborations to investigate the role of protein phosphorylation in heart disease and following stroke, as well as investigating tetraspanins as novel biomarkers in prostate cancer, and protein phosphatase 2A (PP2A) reactivators as new treatments for leukaemia and breast cancer.
Qualifications
- PhD, University of Newcastle
Keywords
- Anti-cancer drugs
- Biochemistry
- Brain cancer
- Breast cancer
- Cancer
- Cancer cell biology
- Cell cycle
- Childhood cancer
- Enzymes
- Leukaemia
- Molecular Targeting
- Prostate cancer
- Protein Phosphorylation
- Proteins
Languages
- English (Fluent)
Fields of Research
Code | Description | Percentage |
---|---|---|
320506 | Medical biochemistry - proteins and peptides (incl. medical proteomics) | 40 |
321101 | Cancer cell biology | 40 |
321105 | Chemotherapy | 20 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Associate Professor | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
1/1/2013 - | Editorial Board - Calcium Signalling | Calcium Signalling Australia |
1/1/2013 - | Membership - Australian Society of Biochemistry and Molecular Biology | Australian Society of Biochemistry and Molecular Biology Australia |
1/1/2012 - 31/12/2015 | Lecturer | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
1/7/2007 - 1/12/2011 | Research Associate | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Membership
Dates | Title | Organisation / Department |
---|---|---|
1/1/2008 - 31/12/2014 | Membership - Australian Neuroscience Society | Australian Neuroscience Society (ANS) Australia |
Invitations
Speaker
Year | Title / Rationale |
---|---|
2015 |
CaMKII – a new target for regulating breast cancer cell invasion and migration Organisation: 8th Annual World Cancer Conference |
2012 |
Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253 Organisation: APSN and JSN Description: Invited presentation |
2010 |
Importance of community support in performing medical research Organisation: NBCF Description: Invited presentation |
2007 |
Use of a common cold-producing virus as a potential treatment for breast cancer Organisation: NBCF Description: Invited presentation |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Chapter (3 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2020 |
Skelding KA, Rostas JAP, 'Regulation of Multifunctional Calcium/Calmodulin Stimulated Protein Kinases by Molecular Targeting', Advances in Experimental Medicine and Biology, Springer, Cham 649-679 (2020) [B1]
|
Nova | |||||||||
2020 |
Skelding KA, Rostas J, 'The Role of Molecular Regulation and Targeting in Regulating Calcium/Calmodulin Stimulated Protein Kinases', Calcium Signaling, Second Edition, Springer New York LLC, New York, NY 649-679 (2020)
|
||||||||||
2012 |
Skelding KA, Rostas JA, 'The role of molecular regulation and targeting in regulating calcium/calmodulin stimulated protein kinases', Calcium Signaling, Springer New York LLC, New York, NY 703-730 (2012) [B1]
|
Nova |
Journal article (39 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Lincz LF, Theron DZ, Barry DL, Scorgie FE, Sillar J, Sefhore O, et al., 'High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia.', Cancers (Basel), 16 (2024) [C1]
|
Nova | |||||||||
2023 |
Rostas JAP, Skelding KA, 'Calcium/Calmodulin-Stimulated Protein Kinase II (CaMKII): Different Functional Outcomes from Activation, Depending on the Cellular Microenvironment.', Cells, 12 401 (2023) [C1]
|
Nova | |||||||||
2022 |
Skelding KA, Barry DL, Theron DZ, Lincz LF, 'Targeting the two-pore channel 2 in cancer progression and metastasis', Exploration of Targeted Anti-tumor Therapy, 3 62-89 (2022) The importance of Ca2+ signaling, and particularly Ca2+ channels, in key events of cancer cell function such as proliferation, metastasis, autophagy and angiogenesis, has recently... [more] The importance of Ca2+ signaling, and particularly Ca2+ channels, in key events of cancer cell function such as proliferation, metastasis, autophagy and angiogenesis, has recently begun to be appreciated. Of particular note are two-pore channels (TPCs), a group of recently identified Ca2+-channels, located within the endolysosomal system. TPC2 has recently emerged as an intracellular ion channel of significant pathophysiological relevance, specifically in cancer, and interest in its role as an anti-cancer drug target has begun to be explored. Herein, an overview of the cancer-related functions of TPC2 and a discussion of its potential as a target for therapeutic intervention, including a summary of clinical trials examining the TPC2 inhibitors, naringenin, tetrandrine, and verapamil for the treatment of various cancers is provided.
|
Nova | |||||||||
2022 |
Skelding KA, Barry DL, Theron DZ, Lincz LF, 'Targeting the two-pore channel 2 in cancer progression and metastasis', Exploration of Targeted Anti-tumor Therapy, 62-89 [C1]
|
Nova | |||||||||
2022 |
Skelding KA, Barry DL, Theron DZ, Lincz LF, 'Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.', Int J Mol Sci, 24 (2022) [C1]
|
Nova | |||||||||
2021 |
Birgersson M, Chi M, Miller C, Brzozowski JS, Brown J, Schofield L, et al., 'A Novel Role for Brain and Acute Leukemia Cytoplasmic (BAALC) in Human Breast Cancer Metastasis', FRONTIERS IN ONCOLOGY, 11 (2021) [C1]
|
Nova | |||||||||
2021 |
Skelding KA, Lincz LF, 'Parp inhibitors and haematological malignancies friend or foe?', Cancers, 13 (2021) [C1] Since their introduction several years ago, poly (ADP-ribose) polymerase (PARP) inhibi-tors (PARPi) have become the standard of care for breast and gynaecological cancers with BRC... [more] Since their introduction several years ago, poly (ADP-ribose) polymerase (PARP) inhibi-tors (PARPi) have become the standard of care for breast and gynaecological cancers with BRCA gene mutations. Given that PARPi act by exploiting defective DNA repair mechanisms within tu-mour cells, they should be ideally suited to combatting haematological malignancies where these pathways are notoriously defective, even though BRCA mutations are rare. To date, despite prom-ising results in vitro, few clinical trials in humans for haematological malignancies have been per-formed, and additional investigation is required. Paradoxically, secondary haematological malignancies have arisen in patients after treatment with PARPi, raising concerns about their potential use as therapies for any blood or bone marrow-related disorders. Here, we provide a comprehensive review of the biological, pre-clinical, and clinical evidence for and against treating individual haematological malignancies with approved and experimental PARPi. We conclude that the prom-ise of effective treatment still exists, but remains limited by the lack of investigation into useful biomarkers unique to these malignancies.
|
Nova | |||||||||
2020 |
Woods JJ, Skelding KA, Martin KL, Aryal R, Sontag E, Johnstone DM, et al., 'Assessment of evidence for or against contributions of Chlamydia pneumoniae infections to Alzheimer's disease etiology', Brain, Behavior, and Immunity, 83 22-32 (2020) [C1] Alzheimer's disease, the most common form of dementia, was first formally described in 1907 yet its etiology has remained elusive. Recent proposals that Aß peptide may be par... [more] Alzheimer's disease, the most common form of dementia, was first formally described in 1907 yet its etiology has remained elusive. Recent proposals that Aß peptide may be part of the brain immune response have revived longstanding contention about the possibility of causal relationships between brain pathogens and Alzheimer's disease. Research has focused on infectious pathogens that may colonize the brain such as herpes simplex type I. Some researchers have proposed the respiratory bacteria Chlamydia pneumoniae may also be implicated in Alzheimer's disease, however this remains controversial. This review aims to provide a balanced overview of the current evidence and its limitations and future approaches that may resolve controversies. We discuss the evidence from in vitro, animal and human studies proposed to implicate Chlamydia pneumoniae in Alzheimer's disease and other neurological conditions, the potential mechanisms by which the bacterium may contribute to pathogenesis and limitations of previous studies that may explain the inconsistencies in the literature.
|
Nova | |||||||||
2020 |
Schofield L, Lincz LF, Skelding KA, 'Unlikely role of glycolytic enzyme -enolase in cancer metastasis and its potential as a prognostic biomarker', Journal of Cancer Metastasis and Treatment, 6 1-12 (2020) [C1]
|
Nova | |||||||||
2019 |
Taylor O, Brzozowski J, Skelding K, 'Glioblastoma multiforme: an overview of emerging therapeutic targets', Frontiers in Oncology, 9 963-963 (2019) [C1]
|
Nova | |||||||||
2019 |
Brzozowski JS, Skelding KA, 'The Multi-Functional Calcium/Calmodulin Stimulated Protein Kinase (CaMK) Family: Emerging Targets for Anti-Cancer Therapeutic Intervention', PHARMACEUTICALS, 12 (2019) [C1]
|
Nova | |||||||||
2018 |
Pearsall EA, Lincz LF, Skelding KA, 'The role of DNA repair pathways in AML chemosensitivity', Current Drug Targets, 19 (2018) [C1]
|
Nova | |||||||||
2018 |
Brzozowski JS, Jankowski H, Bond DR, McCague SB, Munro BR, Predebon MJ, et al., 'Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines.', Lipids Health Dis, 17 211 (2018) [C1]
|
Nova | |||||||||
2018 |
Brzozowski JS, Bond DR, Jankowski H, Goldie BJ, Burchell R, Naudin C, et al., 'Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion', Scientific Reports, 8 1-13 (2018) [C1]
|
Nova | |||||||||
2017 |
Rostas JAP, Spratt NJ, Dickson PW, Skelding KA, 'The role of Ca Studies in multiple experimental systems show that Ca2+-calmodulin stimulated protein kinase II (CaMKII) is a major mediator of ischaemia-induced cell death and suggest that CaMKI... [more] Studies in multiple experimental systems show that Ca2+-calmodulin stimulated protein kinase II (CaMKII) is a major mediator of ischaemia-induced cell death and suggest that CaMKII would be a good target for neuroprotective therapies in acute treatment of stroke. However, as CaMKII regulates many cellular processes in many tissues any clinical treatment involving the inhibition of CaMKII would need to be able to specifically target the functions of ischaemia-activated CaMKII. In this review we summarise new developments in our understanding of the molecular mechanisms involved in ischaemia-induced CaMKII-mediated cell death that have identified ways in which such specificity of CaMKII inhibition after stroke could be achieved. We also review the mechanisms and phases of tissue damage in ischaemic stroke to identify where and when CaMKII-mediated mechanisms may be involved.
|
Nova | |||||||||
2017 |
Rostas JAP, Hoffman A, Murtha LA, Pepperall D, McLeod DD, Dickson PW, et al., 'Ischaemia- and excitotoxicity-induced CaMKII-Mediated neuronal cell death: The relative roles of CaMKII autophosphorylation at T286 and T253', Neurochemistry International, 104 6-10 (2017) [C1] Ischaemia/excitotoxicity produces persistent activation of CaMKII (Ca2+-calmodulin stimulated protein kinase II) that initiates cell death. This study investigated the involvement... [more] Ischaemia/excitotoxicity produces persistent activation of CaMKII (Ca2+-calmodulin stimulated protein kinase II) that initiates cell death. This study investigated the involvement of CaMKII phosphorylation at T286 and T253 in producing this persistent activation. In T286A-aCaMKII transgenic mice that lack the ability to phosphorylate aCaMKII at T286, transient occlusion of the middle cerebral artery for 90¿min resulted in no significant difference in infarct size compared to normal littermate controls. Overexpression of the phospho-mimic mutant T286D-aCaMKII in differentiated neuroblastoma cell lines did not enhance excitotoxicity-induced cell death compared to overexpression of wild type aCaMKII. By contrast, overexpression of the phospho-mimic mutant T253D-aCaMKII significantly enhanced excitotoxicity-induced cell death whereas overexpression of the phospho-null mutant T253V-aCaMKII produced no enhancement. These results indicate that T286 phosphorylation does not play a significant role in ischaemia/excitotoxicity induced CaMKII-mediated cell death and suggest that T253 phosphorylation is required to produce the persistent activation of CaMKII involved in ischaemia/excitotoxicity induced cell death.
|
Nova | |||||||||
2016 |
Chi M, Evans H, Gilchrist J, Mayhew J, Hoffman A, Pearsall EA, et al., 'Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells', SCIENTIFIC REPORTS, 6 (2016) [C1]
|
Nova | |||||||||
2016 |
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7 47465-47478 (2016) [C1] Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leuke... [more] Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP2A inhibition sensitizes cells to the pharmacological PP2A activators, FTY720 and AAL(S). FTY720 and AAL(S) induced cell death and inhibited colony formation of FLT3 activated cells. Furthermore, PP2A activators reduced the phosphorylation of ERK and AKT, downstream targets shared by both FLT3 and PP2A, in FLT3/ITD+ BaF3 and MV4-11 cell lines. PP2A activity was lower in primary human bone marrow derived AML blasts compared to normal bone marrow, with blasts from FLT3-ITD patients displaying lower PP2A activity than WT-FLT3 blasts. Reduced PP2A activity was associated with hyperphosphorylation of the PP2A catalytic subunit, and reduced expression of PP2A structural and regulatory subunits. AML patient blasts were also sensitive to cell death induced by FTY720 and AAL(S), but these compounds had minimal effect on normal CD34+ bone marrow derived monocytes. Finally, PP2A activating compounds displayed synergistic effects when used in combination with tyrosine kinase inhibitors in FLT3-ITD+ cells. A combination of Sorafenib and FTY720 was also synergistic in the presence of a protective stromal microenvironment. Thus combining a PP2A activating compound and a FLT3 inhibitor may be a novel therapeutic approach for treating AML.
|
Nova | |||||||||
2014 |
Skelding KA, Arellano JM, Powis DA, Rostas JA, 'Excitotoxic stimulation of brain microslices as an in vitro model of stroke.', J Vis Exp, e51291 (2014) [C1]
|
Nova | |||||||||
2014 |
Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1] Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation... [more] Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation. The biological properties of CaMKII are regulated by multi-site phosphorylation and targeting via interactions with specific proteins. To investigate the role specific CaMKII phosphorylation sites play in controlling cell proliferation and cell cycle progression, we examined phosphorylation of CaMKII at two sites (T253 and T286) at various stages of the cell cycle, and also examined the effects of overexpression of wild-type (WT), T286D phosphomimic, T253D phosphomimic and T253V phosphonull forms of CaMKIIa in MDA-MB-231 breast cancer and SHSY5Y neuroblastoma cells on cellular proliferation and cell cycle progression. We demonstrate herein that whilst there is no change in total CaMKII expression or T286 phosphorylation throughout the cell cycle, a marked dephosphorylation of CaMKII at T253 occurs during the G2 and/or M phases. Additionally, we show by molecular inhibition, as well as pharmacological activation, that protein phosphatase 2A (PP2A) is the phosphatase responsible for this dephosphorylation. Furthermore, we show that inducible overexpression of WT, T286D and T253V forms of CaMKIIa in MDA-MB-231 and SHSY5Y cells increases cellular proliferation, with no alteration in cell cycle profiles. By contrast, overexpression of a T253D phosphomimic form of CaMKIIa significantly decreases proliferation, and cells accumulate in mitosis, specifically in metaphase. Taken together, these results strongly suggest that the dephosphorylation of CaMKII at T253 is involved in controlling the cell cycle, specifically the metaphase-anaphase transition. © 2014 Elsevier Inc.
|
Nova | |||||||||
2014 |
Abdul Majeed ABB, Pearsall E, Carpenter H, Brzozowski J, Dickson PW, Rostas JAP, Skelding KA, 'CaMKII Kinase Activity, Targeting and Control of Cellular Functions: Effect of Single and Double Phosphorylation of CaMKIIa', Calcium Signaling, 1 36-51 (2014) [C1]
|
Nova | |||||||||
2014 |
Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
|
Nova | |||||||||
2013 |
Skelding KA, Majeed ABA, Carpenter H, Dickson PW, Rostas JA, 'Can functional outcomes of CaMKII double phosphorylation be predicted from outcomes following single phosphorylation of CaMKII?', JOURNAL OF NEUROCHEMISTRY, 125 162-162 (2013) [E3]
|
||||||||||
2012 |
Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
|
||||||||||
2012 |
Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is Differentially Regulated in Striatum and Cortex', JOURNAL OF NEUROCHEMISTRY, 123 63-63 (2012) [E3]
|
Nova | |||||||||
2012 |
Majeed ABA, Rostas JAP, Carpenter H, Dickson PW, Skelding KA, 'Multi-site phosphorylation of CaMKII regulates CaMKII function co-operatively', JOURNAL OF NEUROCHEMISTRY, 123 116-116 (2012) [E3]
|
Nova | |||||||||
2012 |
Skelding KA, Barry RD, Shafren DR, 'Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride', Investigational New Drugs, 30 568-581 (2012) [C1]
|
Nova | |||||||||
2012 |
Skelding KA, Spratt NJ, Fluechter L, Dickson PW, Rostas JA, 'alpha CaMKII is differentially regulated in brain regions that exhibit differing sensitivities to ischemia and excitotoxicity', Journal of Cerebral Blood Flow and Metabolism, 32 2181-2192 (2012) [C1]
|
||||||||||
2011 |
Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
|
Nova | |||||||||
2010 |
Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
|
Nova | |||||||||
2009 |
Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, 110, Suppl. 2 42 (2009) [E3]
|
||||||||||
2009 |
Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, 110, Suppl. 2 40-41 (2009) [E3]
|
||||||||||
2009 |
Skelding KA, Barry RD, Shafren DR, 'Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21', Breast Cancer Research and Treatment, 113 21-30 (2009) [C1]
|
Nova | |||||||||
2009 |
Skelding KA, Rostas JA, 'Regulation of CaMKII in vivo: The importance of targeting and the intracellular microenvironment', Neurochemical Research, 34 1792-1804 (2009) [C1]
|
Nova | |||||||||
2008 |
Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, 106 51 (2008) [E3]
|
||||||||||
2006 |
Skelding KA, Hickey DK, Horvat JC, Bao SS, Roberts KG, Read JM, et al., 'Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection', Vaccine, 24 355-366 (2006) [C1]
|
Nova | |||||||||
2004 |
Howland LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, et al., 'Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection', Infection and Immunity, 72 1019-1028 (2004) [C1]
|
||||||||||
2004 |
Hickey DK, Jones RC, Bao S, Blake AE, Skelding KA, Howland LJ, Beagley KW, 'Intranasal immunization with C.muridarum major outer membrane protein (MOMP) and cholera toxin elicits local production of neutralising IgA in the prostate', Vaccine, 22(31-32) 4306-4315 (2004) [C1]
|
||||||||||
Show 36 more journal articles |
Conference (78 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2021 |
Barry D, Theron D, Enjeti A, Sillar J, Lincz L, Skelding K, 'Increased Alpha-Enolase Expression is Associated with Decreased AML Patient Survival Rate', Asia Pacific Journal of Clinical Oncology, Newcastle (2021)
|
||||
2021 |
Miller C, Lincz L, Skelding K, 'Alpha-enolase regulates tumour cell invasion of breast cancer cells via interaction with BAALC', Alpha-enolase regulates tumour cell invasion of breast cancer cells via interaction with BAALC, Newcastle (2021)
|
||||
2020 |
Jankowski H, Munro B, Brzozowski J, Scarlett C, Skelding K, Weidenhofer J, 'Extracellular vesicles identify novel prostate cancer biomarkers', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
|
||||
2015 | Pearsall E, Chi M, Yoon E-J, Gilchrist J, Verrills N, Skelding K, 'BAALC CAN CONTROL THE SENSITIVITY OF AML CELLS TO CHEMOTHERAPEUTICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) | ||||
2015 |
Pearsall E, Chi M, Yoon E-J, Gilchrist J, Verrills N, Skelding KA, 'BAALC can control the sensitivity of AML cells to chemotherapeutics', The 2015 Hunter Cancer Research Symposium Program, Newcastle (2015) [E3]
|
||||
2015 | Chi M, Brown J, Pearsall E, Gilchrist J, Skelding KA, 'Characterising a novel mechanism for controlling breast cancer cell metastasis', Newcastle (2015) [E3] | ||||
2015 |
Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding KA, Weidenhofer J, 'Differences in extracellular vesicle nucleic acid content show promise as prostate cancer biomarkers', Boston, MA (2015) [O1]
|
||||
2015 |
Watt LF, Panicker N, Copeland B, Kahl RGS, Dun MD, Young B, et al., 'PP2A a novel biomarker and therapeutic target for poor outcome breast cancer', Proceedings of the Lowy Cancer Conference, Sydney (2015) [E3]
|
||||
2015 | Rostas JAP, Hoffman A, Murtha L, Pepperall D, McLeod D, Dickson PW, et al., 'Ischaemia-induced neuronal cell death is mediated by molecular targeting of CaMKII phosphorylated at T253', Proceedings of the First IBRO-APRC Frontiers in Neuroscience, Mumbai, India (2015) [O1] | ||||
2015 | Chi M, Evans H, Gilchrist J, Mayhew J, Hoffman A, Skelding KA, 'CaMKII a new target for regulating breast cancer cell invasion and migration', Proceedings of the 8th Annual World Cancer Conference (Cancer2015), Beijing (2015) [O1] | ||||
2015 |
Rostas J, Hoffman A, Murtha L, Pepperall D, McLeod D, Dickson P, et al., 'Ischaemia-induced neuronal cell death is mediated by molecular targeting of CaMKII phosphorylated at T253', JOURNAL OF NEUROCHEMISTRY, Cairns, AUSTRALIA (2015) [E3]
|
||||
2015 |
Brzozowski J, Coldie B, Jankowski H, Bond D, Scarlett C, Dun M, et al., 'THE EFFECTS OF ALTERED CD9 AND CD151 EXPRESSION ON PROSTATE EXOSOMES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
||||
2015 |
Jankowski H, Goldie B, Brzozowski J, Bond D, Scarlett C, Skelding K, Weidenhofer J, 'PROSTATE CANCER BIOMARKERS: ARE EXTRACELLULAR VESICLES THE SOLUTION?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
||||
2015 |
Mannan A, Panicker N, Watt L, Kahl R, Dun M, Skelding K, Verrills N, 'ROLE OF REDUCED PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, EXPRESSION IN LUMINAL B BREAST CANCER CELL LINE DNA DAMAGE REPAIR PATHWAY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
||||
2015 |
Panicker N, Watt L, Kahl R, Dun M, Greer P, Skelding K, Verrills N, 'REDUCED EXPRESSION OF PROTEIN PHOSPHATASE 2A SUBUNIT, B55A, IN BREAST CANCER DNA DAMAGE REPAIR PATHWAYS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
||||
2014 |
Yoon E-J, Chi MN, Enjeti AK, Verrills NM, Skelding KA, 'CHARACTERISING A NEW TARGET FOR THE TREATMENT OF ACUTE LEUKAEMIAS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
||||
2013 |
Rostas JAP, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is differentially regulated in striatum and cortex', JOURNAL OF MOLECULAR NEUROSCIENCE (2013)
|
||||
2012 |
Skelding KA, Abdul Majeed ABB, Dickson PW, Spratt NJ, Rostas JA, 'CAMKII is regulated differently in brains regions with differing sensitivities to ischaemia/excitotoxicity', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
|
||||
2012 |
Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
|
||||
2012 |
Abdul Majeed ABB, Skelding KA, Dickson PW, Rostas JA, 'Does phosphorylation of CaMKII at multiple sites regulate CaMKII targeting co-operatively or independently?', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
|
||||
2012 |
Rostas JA, Skelding KA, Fluechter L, Dickson PW, Spratt NJ, 'CaMKII is differentially regulated in striatum and cortex', Journal of Molecular Neuroscience: Abstracts The 21st Annual Meeting of the Israel Society for Neuroscience & The First Binational Australian-Israeli Meeting in Neuroscience, Eilat, Israel (2012) [E3]
|
||||
2011 |
Skelding KA, Chung S, Pepperall D-G, Tomkins AJ, Spratt NJ, Rostas JA, 'The role of CaMKII in neuronal sensitivity to ischaemia', Oral abstracts. Australian Neuroscience Society Annual Meeting, Auckland, NZ (2011) [E3]
|
||||
2011 |
Rostas JA, Skelding KA, Banu A, Dickson PW, 'FUNCTIONAL PROPERTIES OF A TRUNCATED alpha-CAMKII MUTANT', JOURNAL OF NEUROCHEMISTRY (2011)
|
||||
2011 |
Skelding KA, Banu A, Chung S, Pepperall D, Tomkins A, Spratt N, Rostas JA, 'THE ROLE OF CAMKII TARGETING IN THE SENSITIVITY OF NEURONAL CELLS TO ISCHAEMIA', JOURNAL OF NEUROCHEMISTRY (2011)
|
||||
2010 |
Rostas JA, Skelding KA, 'The role of targeting in the regulation of CaMKII in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology Symposium Abstracts, Melbourne, Vic (2010) [E3]
|
||||
2010 |
Skelding KA, Tomkins AJ, Fluechter L, Pepperall D-G, Spratt NJ, Rostas JA, 'Ischaemia-induced CaMKII phosphorylation in hypertensive and normotensive rats', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
|
||||
2010 |
Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
|
||||
2010 |
Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
|
||||
2009 |
Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
|
||||
2009 |
Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
|
||||
2008 |
Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
|
||||
2007 |
Skelding KA, Johansson ES, Au GG, Barry RD, Shafren DR, 'CAVATAK TM has anti-cancer properties against human metastatic breast cancer', Fourth International Conference on Oncolytic Viruses as Cancer Therapeutics, Carefree, Arizona (2007) [E3]
|
||||
2006 |
Au GG, Johansson ES, Berry L, Skelding KA, Haley ES, Barry RD, Shafren DR, 'Coxsackievirus A21 as an oncolytic virotherapy agent for human cancers', Northern Lights EUROPIC 2006, Inari, Finland (2006) [E3]
|
||||
2005 |
Shafren DR, Au GG, Berry LJ, Haley ES, Skelding KA, Barry RD, 'The human enterovirus, Coxsackievirus A21, exhibits oncolytic activity across a spectrum of cancer types', Proceedings of the 96th American Association for Cancer Research Annual Meeting, Anaheim, California (2005) [E3]
|
||||
2005 |
Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Combined transcutaneous and intranasal immunisation protects against genital tract Chlamydial infection', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts, USA. (2005) [E3]
|
||||
2005 |
Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Comparison of intranasal and transcutaneous immunisation for the protection against Chlamydial pneumonia', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts (2005) [E3]
|
||||
2005 |
Berry LJ, Haley ES, Skelding KA, Au GG, Barry RD, Shafren DR, 'Oncolytic activity of enteroviruses across a spectrum of human cancer types', Third Annual Australian Virology Group Meeting, Phillip Island, VIC (2005) [E3]
|
||||
2004 | Beagley KW, Skelding KA, Hickey DK, Roberts KG, Bao S, 'Combined transcutaneous and intranasal immunization protects against genital tract Chlamydia infection', American Journal of Reproductive Immunology, St Louis, Missouri (2004) [E3] | ||||
2004 | Skelding KA, Haley ES, Shafren DR, Barry RD, 'Viral oncolysis of human breast cancer', The Hunter Medical Research Institute Inaugural Cancer Conference, - (2004) [E3] | ||||
2003 | Berry L, Hickey DK, Skelding KA, Bao S, Hansbro PM, Beagley KW, 'Transcutaneous immunisation prevents Chlamydia muridarum genital tract infection', American Journal of Reproductive Immunology, - (2003) [E3] | ||||
Show 75 more conferences |
Grants and Funding
Summary
Number of grants | 30 |
---|---|
Total funding | $2,020,752 |
Click on a grant title below to expand the full details for that specific grant.
20211 grants / $122,000
Cracking the Code: The launch of a genomic, epigenetic and proteomic pre-clinical platform to improve the treatment of paediatric leukemias$122,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Matt Dun, Associate Professor Nikki Verrills, Doctor Heather Lee, Doctor Janis Chamberlain, Doctor Frank Alvaro, Doctor Anoop Enjeti, Associate Professor Kathryn Skelding, Doctor Lisa Lincz, Doctor Abdul Mannan, Doctor Heather Murray, Kristy McCarthy, Elizabeth Heskett, Paola Baeza, Kathleen Irish |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2001337 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20182 grants / $199,997
A new biomarker to predict response to PARP inhibitors in glioblastoma$100,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801446 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Investigating a new class of drugs for the treatment of brain cancer$99,997
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1701638 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20171 grants / $25,000
Re-purposing PARP inhibitors to treat childhood leukaemias$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Professor Nikola Bowden, Doctor Lisa Lincz, Doctor Anoop Enjeti, Doctor Frank Alvaro |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1701561 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20161 grants / $5,000
Equipment Grant: Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer$5,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Mr Joshua Brzozowski, Doctor Jude Weidenhofer, Associate Professor Kathryn Skelding, Professor Christopher Scarlett |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | G1601042 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
20157 grants / $601,190
A novel biomarker for luminal B breast cancer$359,577
Funding body: Cancer Council NSW
Funding body | Cancer Council NSW |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2017 |
GNo | G1400487 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$124,938
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Associate Professor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Professor Christopher Scarlett, Professor Pradeep Tanwar, Associate Professor Kathryn Skelding, Doctor Rick Thorne, Professor Nikola Bowden |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2016 |
GNo | G1500598 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Live cell imager for enhancement of pre-clinical cancer studies in the Hunter Translational Cancer Research Centre$25,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Conjoint Professor Stephen Ackland, Associate Professor Kelly Kiejda, Associate Professor Kevin Spring, Professor Xu Dong Zhang, Associate Professor Deborah Marsh, Professor Christopher Scarlett, Professor Pradeep Tanwar, Associate Professor Kathryn Skelding, Doctor Rick Thorne, Professor Nikola Bowden |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500953 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
A novel approach to cancer therapy - targeting patients with loss of a specific tumour suppressor gene$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1501201 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Mengna Chi, Associate Professor Nikki Verrills, Doctor Roger Liang |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600224 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
BAALC - a novel target for the development of new treatments for brain cancer.$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Doctor Craig Gedye |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1600225 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Too Much of a Good Thing: Application for a triple-gas incubator to allow cell culture under normal conditions$16,675
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Craig Gedye, Professor Rodney Scott, Professor Nikola Bowden, Professor Simon Keely, Associate Professor Kathryn Skelding |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | G1500730 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20147 grants / $832,699
Tetraspanin CD9; more than just an exosome marker - A novel biomarker to target for prostate cancer$400,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Jude Weidenhofer, Associate Professor Kathryn Skelding, Professor Matt Dun, Ms Belinda Goldie, Doctor Danielle Bond |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2017 |
GNo | G1400921 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Identification of BAALC as a new target for the treatment of acute myeloid leukaemia$200,000
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Associate Professor Kathryn Skelding |
Scheme | Priority-driven Collaborative Cancer Research Scheme |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2015 |
GNo | G1300551 |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | Y |
Visualisation of microparticles for development of biomarkers and targeted drug delivery mechanisms$125,199
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Christopher Scarlett, Associate Professor Kathryn Skelding, Doctor Jude Weidenhofer, Professor Matt Dun, Associate Professor Kelly Kiejda, Professor Adam McCluskey, Doctor Elham Sadeqzadeh, Professor Hubert Hondermarck, Doctor Rick Thorne, Professor Rodney Scott |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1400627 |
Type Of Funding | Other Public Sector - State |
Category | 2OPS |
UON | Y |
Developing Synthetic Exosomes to Target and Deliver Anti-Cancer Agents to Prostate Cancer Cells$37,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Mr Joshua Brzozowski, Doctor Jude Weidenhofer, Associate Professor Kathryn Skelding |
Scheme | Postgraduate Research Scholarship |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2016 |
GNo | G1401405 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Myr-C310: A new treatment for childhood leukaemia$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301349 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Preclinical testing of a novel therapeutic strategy for breast cancer $25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301439 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills |
Scheme | Near Miss Grant |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1301404 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20132 grants / $49,596
Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1301348 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Ultra-Low Temperature Cryogenic Freezer$24,596
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Jude Weidenhofer, Doctor Rick Thorne, Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills, Professor Pradeep Tanwar, Associate Professor Phillip Dickson, Professor Murray Cairns, Professor Hubert Hondermarck, Professor Xu Dong Zhang, Associate Professor Estelle Sontag, Doctor Chen Chen Jiang, Prof LIZ Milward, Doctor Jean-Marie Sontag, Associate Professor Paul Tooney, Doctor Severine Roselli Dayas, Professor Matt Dun, Professor Chris Dayas, Doctor Lin Kooi Ong, Professor Dirk Van Helden, Mr Ben Copeland, Doctor Gabrielle Briggs, Emeritus Professor Leonie Ashman, Emeritus Professor John Rostas |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1201189 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20123 grants / $55,570
Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Murray Cairns, Associate Professor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1100983 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones |
Scheme | Near Miss Grant |
Role | Investigator |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1200679 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
The 11th Biennial meeting of the Asian Pacific Society for Neurochemistry and the 55th Annual meeting of the Japanese Society for Neurochemistry, Kobe Conference Centre, 30 September - 2 October 2012$1,570
Funding body: University of Newcastle - Faculty of Health and Medicine
Funding body | University of Newcastle - Faculty of Health and Medicine |
---|---|
Project Team | Associate Professor Kathryn Skelding |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2013 |
GNo | G1201010 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20113 grants / $63,200
Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills, Emeritus Professor John Rostas |
Scheme | Breast Cancer Project Grant |
Role | Lead |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1001005 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
Role of CaMKII targeting in stroke susceptibility and outcome$18,200
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Emeritus Professor John Rostas, Professor Neil Spratt, Associate Professor Kathryn Skelding |
Scheme | Stroke Research Project Grant |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1001013 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
IMPLEN NanoPhotometer pearl$10,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Prof ULLI Schall, Associate Professor Phillip Dickson, Professor Rohan Walker, Doctor Rick Thorne, Professor Chris Dayas, Associate Professor Nikki Verrills, Doctor Janet Bristow, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Doctor Jude Weidenhofer, Prof LIZ Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Doctor Dan Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1100030 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20101 grants / $34,000
ABI 7500 Real Time PCR System $34,000
Funding body: NHMRC (National Health & Medical Research Council)
20091 grants / $1,700
The 22nd Biennial Meeting of the ISN/APSN Joint Meeting, Busan South Korea, 23-28 August 2009$1,700
Funding body: University of Newcastle - Faculty of Health and Medicine
Funding body | University of Newcastle - Faculty of Health and Medicine |
---|---|
Project Team | Associate Professor Kathryn Skelding |
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2009 |
Funding Finish | 2009 |
GNo | G0190587 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
20051 grants / $30,800
Viral Oncolysis of Human Breast Cancer$30,800
Funding body: National Breast Cancer Foundation
Funding body | National Breast Cancer Foundation |
---|---|
Project Team | Associate Professor Kathryn Skelding |
Scheme | Postgraduate Research Scholarship |
Role | Lead |
Funding Start | 2005 |
Funding Finish | 2005 |
GNo | G0184441 |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2024 | PhD | Examination of Tetrandrine as a Potential Treatment for AML and MDS | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2021 | PhD | Studies of Respiratory Chlamydia Infections in Mouse Models of Chlamydia Infection and Alzheimer’s Disease | PhD (Medical Genetics), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2019 | PhD | Identification of Biomarkers and Novel Targets for Prostate Cancer from Extracellular Vesicles | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2019 | PhD | The Functional Role of PPP2R2A in Luminal Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2018 | PhD | Characterisation of the Membrane Composition and Function of Extracellular Vesicles from Prostate Cells | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2016 | Honours | DNA repair in acute myeloid leukaemia | Biochemistry & Cell Biology, UoN | Principal Supervisor |
2015 | Honours | BAALC over expression: a new mechanism controlling sensitivity to chemotherapeutic agents in acute myeloid leukaemia | Biochemistry & Cell Biology, UoN | Principal Supervisor |
2014 | Honours | BAALC: A new target for the treatment of childhood leukaemia | Biochemistry & Cell Biology, UoN | Principal Supervisor |
2013 | Honours | Role of tetraspanins in prostate cancer exosome functions | Biochemistry & Cell Biology, UoN | Co-Supervisor |
2013 | Masters | Effects of Multi-site Phosphorylation on CaMKII Function | M Philosophy (Medical Biochem), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2013 | Honours | PP2A reactivation as a new treatment for breast cancer | Biochemistry & Cell Biology, UoN | Co-Supervisor |
2011 | Honours | The role of protein phosphatase 2A in FLT3+ leukaemia | Biochemistry & Cell Biology, UoN | Co-Supervisor |
2010 | Honours | Controlling the cell cycle - the role of CaMKII | Biochemistry & Cell Biology, UoN | Co-Supervisor |
News
News • 4 Feb 2014
Debunking myths about cancer
University of Newcastle researchers are debunking myths as they pave the way forward in cancer research.
Associate Professor Kathryn Skelding
Position
Associate Professor
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Focus area
Medical Biochemistry
Contact Details
kathryn.skelding@newcastle.edu.au | |
Phone | (02) 4921 5982 |
Fax | (02) 4921 6903 |
Office
Room | MS610 |
---|---|
Building | Life Sciences |
Location | Callaghan University Drive Callaghan, NSW 2308 Australia |